ESMO 2023 | SAKK 11/16: MVX-ONCO-1, a novel vaccine, in pre-treated RMHNSCC

Nicolas Mach, MD, Hôpitaux Universitaires de Genève, Geneva, Switzerland, discusses findings from the Phase IIa SAKK 11/16 trial (NCT02999646) of MVX-ONCO-1, a vaccine for patients with pre-treated recurrent/metastatic head & neck squamous cell carcinoma (RMHNSCC). Patients have typically progressed on pembrolizumab or nivolumab and the vaccine resulted in prolonged survival, where a few cases of complete response reported. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.